$0.50
2.00% yesterday
Nasdaq, Dec 23, 10:00 pm CET
ISIN
US4268971045
Symbol
HEPA
Sector
Industry

Hepion Pharmaceuticals Inc Stock price

$0.50
-0.18 26.81% 1M
-0.57 53.28% 6M
-2.74 84.57% YTD
-2.80 84.85% 1Y
-25.70 98.09% 3Y
-107.10 99.54% 5Y
-23,407.50 100.00% 10Y
Nasdaq, Closing price Mon, Dec 23 2024
+0.01 2.02%
ISIN
US4268971045
Symbol
HEPA
Sector
Industry

Key metrics

Market capitalization $3.48m
Enterprise Value $5.90m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-25.36m
Free Cash Flow (TTM) Free Cash Flow $-26.07m
Cash position $1.50m
EPS (TTM) EPS $-4.39
Short interest 1.13%
Show more

Is Hepion Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.

Hepion Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Hepion Pharmaceuticals Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast Hepion Pharmaceuticals Inc:

Hold
100%

Financial data from Hepion Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.04 0.04
43% 43%
-
-0.04 -0.04
43% 43%
-
- Selling and Administrative Expenses 7.40 7.40
8% 8%
-
- Research and Development Expense 18 18
53% 53%
-
-25 -25
45% 45%
-
- Depreciation and Amortization 0.04 0.04
43% 43%
-
EBIT (Operating Income) EBIT -25 -25
45% 45%
-
Net Profit -23 -23
49% 49%
-

In millions USD.

Don't miss a Thing! We will send you all news about Hepion Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hepion Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
13 days ago
EDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has entered into a termination agreement with Pharma Two B L...
Neutral
GlobeNewsWire
19 days ago
KIRYAT ONO, Israel, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Pharma Two B , a private, late-stage pharmaceutical company developing innovative combination drugs for neurological disorders, today announced a poster presentation of integrated safety and efficacy data on P2B001 from its Phase 2b and Phase 3 studies in early-stage Parkinson's disease (PD) patients. P2B001 is a fixed, low-dose extended-rel...
Neutral
GlobeNewsWire
22 days ago
Transaction Creates Opportunity to Share in Potential Upside of Pharma Two B's Late-Clinical Stage Candidate to Treat Parkinson's Disease
More Hepion Pharmaceuticals Inc News

Company Profile

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Head office United States
CEO John Brancaccio
Employees 22
Founded 2013
Website www.hepionpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today